Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview
American Journal of Hematology · 2026-04 · 101 (S1) · 56-74
DOI: 10.1002/ajh.70221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 14.03.2026. Verfasst von Adetola A Kassim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University M…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The practical aspects of developing curative treatments for sickle cell disease (SCD) in Africa, such as gene therapy and hematopoietic stem cell transplantation, involve strengthening healthcare infrastructure, training healthcare professionals, establishing regional treatment centers, and creating national SCD programs. The costs associated with gene therapy and stem cell transplants can be prohibitive, especially in low‐ and middle‐income countries. Strategies to address affordability, including local manufacturing, government funding, and partnerships with global health agencies, are essential to ensure equitable access. Establishing ethical and regulatory guidelines while raising awareness among patients and communities is critical. Early diagnosis through newborn screening and adequate clinical care programs are vital for identifying individuals with SCD who could benefit from curative therapies and other interventions. Addressing cultural beliefs and promoting positive attitudes toward SCD and its management is essential. While curative therapies offer hope, hydroxyurea and other disease‐modifying therapies with established clinical benefits are more accessible in many settings. Prioritizing these medications ensures that patients with SCD are medically prepared to receive curative therapies while simultaneously building capacity for advanced treatments, thus creating a pragmatic approach. Lastly, international collaboration and partnerships among researchers, global health agencies, and local organizations are vital for sharing knowledge, resources, and best practices in SCD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pediatrics, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Adetola A Kassim
Zitieren
APA
Kassim, A. A., Thompson, A. A., & Malik, P. (2026). Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview. American Journal of Hematology, 101(S1), 56-74. https://doi.org/10.1002/ajh.70221
Vancouver
Kassim AA, Thompson AA, Malik P. Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview. American Journal of Hematology. 2026;101(S1):56-74. doi:10.1002/ajh.70221
BibTeX
@article{Kassim2026,
author = {Kassim, Adetola A and Thompson, Alexis A and Malik, Punam},
title = {Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {S1},
pages = {56--74},
doi = {10.1002/ajh.70221}
}
EUVIMED